Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

Hannah joined The Scientist as an assistant editor in 2023. She earned her PhD in neuroscience from the University of Washington in 2017 and completed the Dalla Lana Fellowship in Global Journalism in ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall.

A placebo is often thought of in terms of a sugar pill but it essentially refers to any treatment or intervention that in itself has no biological effect - e.g. a saline injection or even ...

Ted Kaptchuk investigates placebo effects and has published over 100 articles — including clinical trials, neuroimaging studies, historical investigations, methodological reviews and ethical ...

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

We wanted to see if people taking the pills would get better anyway? The placebo effect is well studied but at the same time something of a mystery. The word placebo comes from the Latin "I shall ...

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers have investigated this with promising results. For the first time, it was possible to identify patient ...

Short-term menopausal hormone therapy (MHT) did not have long-term cognitive effects when given to women in early postmenopause, according to a study published November 21 in the journal PLOS ...